文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

小鼠双特异性抗体体内有效重定向T细胞攻击CALR突变干细胞

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.
PubMed 文献 · Am J Hematol · 2026-01-14

该研究开发了双特异性T细胞衔接抗体DX1-2C11,靶向由MPL呈递的突变钙网蛋白(mutCALR)。体外实验显示DX1-2C11以剂量依赖方式清除表达mutCALR的Ba/F3细胞及原代小鼠髓系细胞;在CALRdel52转基因小鼠中,单次给药24小时内激活外周血、脾和骨髓的CD4+与CD8+ T细胞,第7天降低外周血小板计数并减少脾和骨髓中突变干/祖细胞群体,且突变负荷降低在二次受体小鼠中持久维持;在播散性NSG模型中,DX1-2C11立即减轻肿瘤负荷并显著延长总生存期。

要点

  • DX1-2C11体外以剂量依赖方式清除表达mutCALR的细胞及原代小鼠髓系细胞。
  • CALRdel52转基因小鼠单次给药后24小时激活T细胞,第7天减少突变干/祖细胞。
  • 播散性NSG模型中DX1-2C11立即减轻肿瘤负荷并显著延长总生存期。

核心结论

  • 靶向mutCALR的双特异性T细胞衔接抗体DX1-2C11可在体内有效清除突变MPN干细胞,提示为潜在治愈策略。

研究设计与样本

  • 临床前研究:开发双特异性T细胞衔接抗体DX1-2C11,在体外细胞系、CALRdel52转基因小鼠及播散性NSG模型中进行评价。

主要发现

  • DX1-2C11体外以剂量依赖方式清除表达mutCALR的Ba/F3细胞及原代小鼠髓系细胞。
  • CALRdel52转基因小鼠单次给药后24小时内激活外周血、脾和骨髓的CD4+与CD8+ T细胞。
  • 单次给药后第7天降低外周血小板计数并减少脾和骨髓中突变干/祖细胞群体。
  • 突变负荷降低在二次受体小鼠中持久维持。
  • 播散性NSG模型中DX1-2C11立即减轻肿瘤负荷并显著延长总生存期。

临床怎么用

  • 支持进一步开发靶向mutCALR的双特异性T细胞衔接抗体用于MPN的免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calreticulin (CALR) mutations are prevalent in 20%-30% of patients with BCR::ABL1-negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease-initiating MPN progenitors, represents an ideal target for curative immunotherapies including monoclonal antibodies, bispecific T cell engaging antibodies (TCE), and CAR-T cell therapies. Despite that two clinical TCE candidates have advanced into phase 1 trials in recent 2 years, depletion of mutCALR+ hematopoietic stem cells and normalization of hematopoiesis remained absent in preclinical evaluation. Here, we developed a bispecific T cell engager DX1-2C11 that specifically and efficiently eradicates mutCALR-expressing cells via recruiting polyclonal T cells. DX1-2C11 depleted Ba/F3 cells expressing mutCALR, as well as primary murine myeloid cells in a dose-dependent manner in vitro. In CALRdel52 transgenic mice, a single dose of DX1-2C11 activated CD4+ and CD8+ T cells in the peripheral blood, spleen and bone marrow within 24 h. Furthermore, a single dose of DX1-2C11 reduced platelet counts in the periphery and decreased mutant stem/progenitor cell populations in the spleen and bone marrow by Day 7 posttreatment. Notably, the reduction of mutant burden was durably maintained in secondary recipient mice. In the disseminated NSG model, DX1-2C11 delivered immediate tumor burden reduction and significantly prolonged the overall survival of mice compared to the control group. Taken together, these data suggest that bispecific T cell engaging antibody targeting mutCALR represents a curative strategy that efficiently eliminates mutant MPN stem cells in vivo.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Xiong S, Wais T, Varga C, et al. A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo. Am J Hematol. 2026. PMID: 41532194. doi:10.1002/ajh.70206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。